[HTML][HTML] Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

Q Zhu, Z Chen, PK Paul, Y Lu, W Wu, J Qi - Acta Pharmaceutica Sinica B, 2021 - Elsevier
Q Zhu, Z Chen, PK Paul, Y Lu, W Wu, J Qi
Acta Pharmaceutica Sinica B, 2021Elsevier
Proteins and peptides (PPs) have gradually become more attractive therapeutic molecules
than small molecular drugs due to their high selectivity and efficacy, but fewer side effects.
Owing to the poor stability and limited permeability through gastrointestinal (GI) tract and
epithelia, the therapeutic PPs are usually administered by parenteral route. Given the big
demand for oral administration in clinical use, a variety of researches focused on developing
new technologies to overcome GI barriers of PPs, such as enteric coating, enzyme inhibitors …
Abstract
Proteins and peptides (PPs) have gradually become more attractive therapeutic molecules than small molecular drugs due to their high selectivity and efficacy, but fewer side effects. Owing to the poor stability and limited permeability through gastrointestinal (GI) tract and epithelia, the therapeutic PPs are usually administered by parenteral route. Given the big demand for oral administration in clinical use, a variety of researches focused on developing new technologies to overcome GI barriers of PPs, such as enteric coating, enzyme inhibitors, permeation enhancers, nanoparticles, as well as intestinal microdevices. Some new technologies have been developed under clinical trials and even on the market. This review summarizes the history, the physiological barriers and the overcoming approaches, current clinical and preclinical technologies, and future prospects of oral delivery of PPs.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果